Literature DB >> 9755928

Metronidazole has no antibacterial effect in Cornell model murine tuberculosis.

J Dhillon1, B W Allen, Y M Hu, A R Coates, D A Mitchison.   

Abstract

SETTING: Experiments in vitro on the bactericidal activity of metronidazole and in the Cornell model of murine tuberculosis.
OBJECTIVE: To assess the sterilising activity of maximal metronidazole dosage and its activity against bacilli held dormant by immunity in the mouse.
DESIGN: In vitro experiments showed that metronidazole was only bactericidal at attainable concentrations (50-100 microg/ml) under anaerobic conditions. In the Cornell model, isoniazid 25 mg/kg and high dosage pyrazinamide 1000 mg/kg was given in the diet with and without 1500 mg/kg metronidazole for the initial 14 weeks of sterilising chemotherapy. In the subsequent sterile state, metronidazole at 0, 100 and 250 mg/kg was given by daily gavage for 6 weeks. Finally, the mice were given 3 weeks of high dosage steroids and their organs were cultured in selective liquid medium.
RESULTS: Metronidazole had no activity either in the initial sterilising phase or in the subsequent sterile state.
CONCLUSION: The O2 tension in the cellular lesions of murine tuberculosis is unlikely to be sufficiently low to allow metronidazole to act. Its activity should be assessed in caseous lesions.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9755928

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  20 in total

Review 1.  Tuberculosis: latency and reactivation.

Authors:  J L Flynn; J Chan
Journal:  Infect Immun       Date:  2001-07       Impact factor: 3.441

2.  Metronidazole validates drugs targeting hypoxic bacteria for improved treatment of tuberculosis.

Authors:  Ying Zhang
Journal:  Proc Natl Acad Sci U S A       Date:  2012-08-15       Impact factor: 11.205

Review 3.  Development of new vaccines and drugs for TB: limitations and potential strategic errors.

Authors:  Ian M Orme
Journal:  Future Microbiol       Date:  2011-02       Impact factor: 3.165

Review 4.  Discovery and development of SQ109: a new antitubercular drug with a novel mechanism of action.

Authors:  Katherine A Sacksteder; Marina Protopopova; Clifton E Barry; Koen Andries; Carol A Nacy
Journal:  Future Microbiol       Date:  2012-07       Impact factor: 3.165

5.  Evaluation of a mouse model of necrotic granuloma formation using C3HeB/FeJ mice for testing of drugs against Mycobacterium tuberculosis.

Authors:  Emily R Driver; Gavin J Ryan; Donald R Hoff; Scott M Irwin; Randall J Basaraba; Igor Kramnik; Anne J Lenaerts
Journal:  Antimicrob Agents Chemother       Date:  2012-04-02       Impact factor: 5.191

6.  Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis.

Authors:  Sang Hyun Cho; Saradee Warit; Baojie Wan; Chang Hwa Hwang; Guido F Pauli; Scott G Franzblau
Journal:  Antimicrob Agents Chemother       Date:  2007-01-08       Impact factor: 5.191

7.  Oxygen depletion-induced dormancy in Mycobacterium bovis BCG.

Authors:  A Lim; M Eleuterio; B Hutter; B Murugasu-Oei; T Dick
Journal:  J Bacteriol       Date:  1999-04       Impact factor: 3.490

8.  Metronidazole plus rifampin sterilizes long-term dormant Mycobacterium tuberculosis.

Authors:  Elisabetta Iona; Federico Giannoni; Manuela Pardini; Lara Brunori; Graziella Orefici; Lanfranco Fattorini
Journal:  Antimicrob Agents Chemother       Date:  2007-01-22       Impact factor: 5.191

9.  Tuberculous granulomas are hypoxic in guinea pigs, rabbits, and nonhuman primates.

Authors:  Laura E Via; P Ling Lin; Sonja M Ray; Jose Carrillo; Shannon Sedberry Allen; Seok Yong Eum; Kimberly Taylor; Edwin Klein; Ujjini Manjunatha; Jacqueline Gonzales; Eun Gae Lee; Seung Kyu Park; James A Raleigh; Sang Nae Cho; David N McMurray; JoAnne L Flynn; Clifton E Barry
Journal:  Infect Immun       Date:  2008-03-17       Impact factor: 3.441

10.  Metronidazole lacks antibacterial activity in guinea pigs infected with Mycobacterium tuberculosis.

Authors:  Donald R Hoff; Megan L Caraway; Elizabeth J Brooks; Emily R Driver; Gavin J Ryan; Charles A Peloquin; Ian M Orme; Randall J Basaraba; Anne J Lenaerts
Journal:  Antimicrob Agents Chemother       Date:  2008-08-11       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.